ES2979314T3 - L-asparaginasa modificada - Google Patents

L-asparaginasa modificada Download PDF

Info

Publication number
ES2979314T3
ES2979314T3 ES18731853T ES18731853T ES2979314T3 ES 2979314 T3 ES2979314 T3 ES 2979314T3 ES 18731853 T ES18731853 T ES 18731853T ES 18731853 T ES18731853 T ES 18731853T ES 2979314 T3 ES2979314 T3 ES 2979314T3
Authority
ES
Spain
Prior art keywords
asparaginase
amino acid
modified protein
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18731853T
Other languages
English (en)
Spanish (es)
Inventor
Lars Friedrich
Anne O'donnell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jazz Pharmaceuticals Ireland Ltd
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP17177237.9A external-priority patent/EP3418383A1/en
Priority claimed from US15/671,086 external-priority patent/US10174302B1/en
Application filed by Jazz Pharmaceuticals Ireland Ltd filed Critical Jazz Pharmaceuticals Ireland Ltd
Application granted granted Critical
Publication of ES2979314T3 publication Critical patent/ES2979314T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C12N9/82—Asparaginase (3.5.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01001—Asparaginase (3.5.1.1)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES18731853T 2017-06-21 2018-06-21 L-asparaginasa modificada Active ES2979314T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762523061P 2017-06-21 2017-06-21
EP17177237.9A EP3418383A1 (en) 2017-06-21 2017-06-21 Modified l-asparaginase
US15/671,086 US10174302B1 (en) 2017-06-21 2017-08-07 Modified L-asparaginase
PCT/EP2018/066647 WO2018234492A1 (en) 2017-06-21 2018-06-21 L-ASPARAGINASE MODIFIED

Publications (1)

Publication Number Publication Date
ES2979314T3 true ES2979314T3 (es) 2024-09-25

Family

ID=64737515

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18731853T Active ES2979314T3 (es) 2017-06-21 2018-06-21 L-asparaginasa modificada

Country Status (15)

Country Link
EP (2) EP3642340B1 (enExample)
JP (2) JP7808424B2 (enExample)
KR (1) KR102727396B1 (enExample)
CN (1) CN111315878B (enExample)
AU (1) AU2018287145B2 (enExample)
BR (1) BR112019027479A2 (enExample)
CA (1) CA3068100A1 (enExample)
DK (1) DK3642340T3 (enExample)
ES (1) ES2979314T3 (enExample)
FI (1) FI3642340T3 (enExample)
IL (1) IL271504B2 (enExample)
MX (2) MX2019015502A (enExample)
SA (2) SA522433360B1 (enExample)
SG (1) SG11201912625QA (enExample)
WO (1) WO2018234492A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7065772B2 (ja) 2015-12-22 2022-05-12 エクスエル‐プロテイン ゲーエムベーハー 低反復性ヌクレオチド配列を有する、プロリンおよびアラニン残基が豊富な反復性アミノ酸配列をコードする核酸
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
ES2979314T3 (es) * 2017-06-21 2024-09-25 Jazz Pharmaceuticals Ireland Ltd L-asparaginasa modificada
EP3713595A1 (en) * 2017-11-22 2020-09-30 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with increased duration of effect
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
CA3156066A1 (en) * 2019-10-25 2021-04-29 Mi Rim Choi Recombinant l-asparaginase
KR20230125179A (ko) * 2020-12-23 2023-08-29 재즈 파마슈티칼즈 아일랜드 리미티드 전하-차폐 융합 단백질의 정제 방법
WO2022211829A1 (en) 2021-03-30 2022-10-06 Jazz Pharmaceuticals Ireland Ltd. Dosing of recombinant l-asparaginase
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US20260007728A1 (en) 2022-07-14 2026-01-08 Jazz Pharmaceuticals Ireland Ltd. Combination therapies involving l-asparaginase

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8519753D0 (en) * 1985-08-06 1985-09-11 Health Lab Service Board Production of 1-asparaginase
GB9017002D0 (en) * 1990-08-02 1990-09-19 Health Lab Service Board Improved method for the purification of erwina l-asparaginase
WO2007103290A2 (en) 2006-03-03 2007-09-13 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Materials and methods directed to asparagine synthetase and asparaginase therapies
EP2851424B1 (en) * 2007-03-09 2016-09-21 Novozymes A/S Thermostable asparaginases
US8563521B2 (en) 2007-06-21 2013-10-22 Technische Universitat Munchen Biological active proteins having increased in vivo and/or in vitro stability
WO2011003633A1 (en) * 2009-07-06 2011-01-13 Alize Pharma Ii Pegylated l-asparaginase
DK2571510T3 (en) * 2010-05-21 2018-11-19 Xl Protein Gmbh BIOSYNTHETIC PROLIN / ALANIN-RANDOM COIL POLYPEPTIDES AND THEIR APPLICATIONS
CN104302408B (zh) 2012-02-27 2016-12-14 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
ES2979314T3 (es) 2017-06-21 2024-09-25 Jazz Pharmaceuticals Ireland Ltd L-asparaginasa modificada

Also Published As

Publication number Publication date
CN111315878A (zh) 2020-06-19
JP2020528743A (ja) 2020-10-01
AU2018287145B2 (en) 2024-04-18
JP2023081915A (ja) 2023-06-13
EP3642340B1 (en) 2024-03-20
WO2018234492A1 (en) 2018-12-27
RU2020101972A3 (enExample) 2021-11-09
AU2018287145A1 (en) 2020-02-06
RU2020101972A (ru) 2021-07-21
CN111315878B (zh) 2024-04-26
IL271504B1 (en) 2024-01-01
MX2019015502A (es) 2020-07-28
SG11201912625QA (en) 2020-01-30
IL271504B2 (en) 2024-05-01
KR20200030065A (ko) 2020-03-19
EP4180525A1 (en) 2023-05-17
FI3642340T3 (fi) 2024-06-18
BR112019027479A2 (pt) 2020-09-15
KR102727396B1 (ko) 2024-11-08
SA519410870B1 (ar) 2023-03-06
SA522433360B1 (ar) 2024-06-23
MX2024015050A (es) 2025-01-09
JP7808424B2 (ja) 2026-01-29
IL271504A (en) 2020-02-27
JP7770352B2 (ja) 2025-11-14
DK3642340T3 (da) 2024-06-03
EP3642340A1 (en) 2020-04-29
CA3068100A1 (en) 2018-12-27

Similar Documents

Publication Publication Date Title
JP7770352B2 (ja) 修飾されたl-アスパラギナーゼ
US11802279B2 (en) Modified L-asparaginase
EP3418383A1 (en) Modified l-asparaginase
ES2636476T5 (es) L-asparaginasa pegilada
ES2647528T3 (es) Polisialilación N-terminal
Wu et al. Precise and combinatorial PEGylation generates a low-immunogenic and stable form of human growth hormone
US8343760B2 (en) p53 activator peptides
WO2013097658A1 (zh) 人精氨酸酶和聚乙二醇化人精氨酸酶及其应用
RS57077B1 (sr) Pegilovana l-asparaginaza
AU2020362820A1 (en) Improved uricase and method for treating hyperuricemia using same
EP4015526A1 (en) Recombinant interleukin-15 analog
AU2018309724B2 (en) Modified DDAH polypeptides comprising a pharmacokinetic enhancing moiety, improved pharmacology and their uses
CN104151432A (zh) 一种抗肿瘤融合蛋白、其编码基因和用途
US20230406927A1 (en) Masked single-domain antibodies and methods thereof
RU2775696C2 (ru) Модифицированная l-аспарагиназа
HK40090811A (en) Modified l-asparaginase
CN108265044B (zh) 聚乙二醇定点修饰的精氨酸脱亚胺酶及其制备方法与应用
HK40029594B (en) Modified l-asparaginase
HK40029594A (en) Modified l-asparaginase
CN121851139A (zh) 定点修饰的偏向性激活白介素-2及其应用
EP4469481A2 (en) Anti-b7-h3 compounds and methods of use